-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

634.O3.6 634. Myeloproliferative Syndromes: Clinical: Clinical Trials in Polycythemia Vera Clinically Relevant Abstract

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Biological, Adult, Diseases, Non-Biological, Therapies, chemical interactions, chemotherapy, MPN, Polycythemia vera, Study Population, Myeloid Malignancies, Clinically relevant, pharmacology, TKI
Sunday, December 6, 2020: 2:00 PM-3:30 PM
Moderators:
Aaron T. Gerds, MD, MS, Cleveland Clinic Taussig Cancer Institute and Tania Jain, MD, Memorial Sloan Kettering Cancer Center
Disclosures:
Jain: Takeda oncology: Consultancy; CareDx: Other: Advisory board; Bristol Myers Squibb: Other: Advisory board .
2:00 PM

John Mascarenhas, MD1, Brian Higgins2*, Doreen Anders3*, Kate Burbury, MD4*, Tarec Christoffer El-Galaly3, Aaron T. Gerds, MD, MS5, Vikas Gupta, MD, FRCP, FRCPath6, Bruno Kovic7*, Margherita Maffioli, MD8*, Ruben Mesa, MD9, Jeanne M. Palmer, Md10, Francesco Passamonti, MD11*, Alessandro Rambaldi, MD12, David M Ross, MBBS, PhD, FRACP, FRCPA13*, Alessandro Vannucchi, MD14 and Abdulraheem Yacoub, MD15

1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
2Genentech, Inc., South San Francisco, CA
3F. Hoffmann-La Roche, Ltd., Basel, Switzerland
4Peter MacCallum Cancer Centre, Melbourne, AUS
5Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
6Princess Margaret Cancer Centre, Toronto, ON, Canada
7F. Hoffmann-La Roche, Ltd., Mississauga, ON, Canada
8ASST Sette Laghi, Ospedale di Circolo, Varese, ITA
9UT Health San Antonio Cancer Center, San Antonio, TX
10Mayo Clinic, Phoenix, AZ
11University of Insubria, Varese, Italy
12Department of Oncology and Hematology University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
13Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia
14Az. Ospedaliero-Universitaria Careggi, Firenze, Italy
15The University of Kansas Cancer Center, Leawood, KS

2:15 PM

Ghaith Abu-Zeinah, MD1*, Spencer Krichevsky, BS1*, Tatiana Cruz, MD1*, Gabriela Hoberman, BA1*, Niamh Savage, BA1*, Ellen Ritchie, MD 2, Joseph Scandura, MD, PhD1 and Richard T. Silver, MD3

1Richard T. Silver, M.D. Myeloproliferative Neoplasms (MPN) Center, Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY
2Weill Cornell Medicine, New York, NY
3Weill Cornell Medical College, New York, NY

2:30 PM

Heinz Gisslinger, MD1*, Christoph Klade, PhD2*, Pencho Georgiev, MD3*, Dorota Krochmalczyk, MD4*, Liana Gercheva-Kyuchukova, MD5*, Miklos Egyed, MD6*, Petr Dulicek, MD7*, Árpád Illés, MD, PhD8*, Halyna Pylypenko, MD9*, Lylia Sivcheva, MD10*, Jiří Mayer11, Vera Yablokova, MD12*, Kurt Krejcy, MD2*, Victoria Empson, MSc2*, Hans C. Hasselbalch, MD13, Robert Kralovics, PhD14 and Jean Jacques Kiladjian, MD, PhD15

1Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University Vienna, Vienna, Austria
2AOP Orphan Pharmaceuticals AG, Vienna, Austria
3Medical University of Plovdiv, Plovdiv, Bulgaria
4Teaching Unit of the Hematology Department, University Hospital in Krakow, Kracow, Poland
5Clinical Hematology Clinic, Multiprofile Hospital For Active Treatment "Sveta Marina", Varna, Bulgaria
6Department of Internal Medicine II, Kaposi Mor Teaching Hospital, Kaposvar, Hungary
7Department of Clinical Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
8Faculty of Medicine, Department of Hematology, University of Debrecen, Debrecen, Hungary
9Regional Treatment and Diagnostics Haematology Centre, Department of Hematology, Cherkasy Regional Oncology Centre, Cherkasy, Ukraine
10First Department of Internal Medicine, Multiprofile Hospital for Active Treatment - HristoBotev, Vratsa, Bulgaria
11Internal Hematology and Oncology Clinic, University Hospital Brno, Brno, Czech Republic
12Department of Hematology, Yaroslavl Regional Clinical Hospital, Yaroslavl, Russian Federation
13Department of Hematology, Zealand University Hospital, Roskilde, Denmark
14Department of Laboratory Medicine, Medical University of Vienna, Research Center For Molecular Medicine of the Austrian Academy of Sciences, Vienna, Wien, Austria
15INSERM UMR 1131, Saint-Louis Research Institute, Paris, France

2:45 PM

Marina Kremyanskaya1,2, Yelena Ginzburg, MD3, Andrew T. Kuykendall, MD4, Abdulraheem Yacoub, MD5, Jay Yang, MD6, Suneel K Gupta, PhD7*, Frank Valone, MD8*, Sarita Khanna, PhD9*, Srdan Verstovsek, MD, PhD10 and Ronald Hoffman, MD1

1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
2Division of Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY
3Division of Hematology Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
4Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
5The University of Kansas Cancer Center, Leawood, KS
6Karmanos Cancer Institute, Detroit, MI
7Protagonist Therapeutics, Sunnyvale, CA
8Protagonist Therapeutics, Mill Valley, CA
9Protagonist Therapeutics, Newark, CA
10Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

3:00 PM

Rafael Daltro De Oliveira, MD1*, Juliette Soret-Dulphy, MD1*, Lin-Pierre Zhao, MD1*, Clemence Marcault2*, Nicolas Gauthier, MD1*, Emmanuelle Verger, PhD3,4*, Nabih Maslah, PharmD3,5*, Nathalie Parquet, MD6*, Emmanuel Raffoux, MD6*, William Vainchenker7*, Christine Chomienne, MD, PhD8,9, Bruno Cassinat, PharmD, PhD3,9*, Lina Benajiba, MD, PhD1,10* and Jean-Jacques Kiladjian, MD, PhD4,11*

1Université de Paris, Clinical Investigations Center, Saint-Louis hospital, APHP, Paris, France
2Saint-Louis, Nice, France
3Université de Paris, Cellular biology Department, Saint-Louis hospital, APHP, Paris, France
4INSERM UMR 1131, Saint-Louis Research Institute, Paris, France
5UMRS_1131, Inserm, Université de Paris, Institut de recherche Saint-Louis, Paris, France
6Université de Paris, Hematology department, Saint-Louis hospital, APHP, Paris, France
7Gustave Roussy, Villejuif, France
8Unité de Biologie cellulaire, Université de Paris, Paris, France
9Institut de Recherche St Louis, Université de Paris, INSERM U1131, Paris, France
10APHP, INSERM U944, Institute of Hematology - St Louis Hospital, PARIS, France
11Université de Paris, Clinical Investigations Center, Saint-Louis hospital, APHP, Paris, FRA

3:15 PM

Brady L. Stein, MD, MHSc1*, Kamal Patel, MD2*, Robyn M. Scherber, MD3,4, Jingbo Yu, MD, PhD3, Dilan Paranagama, PhD3* and Carole B. Miller, MD5

1Northwestern University Feinberg School, Chicago, IL
2CARTI Cancer Center, Little Rock, AR
3Incyte Corporation, Wilmington, DE
4UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
5St Agnes Cancer Center, Baltimore, MD

*signifies non-member of ASH